Taiyen Biotech Co Ltd (1737) - Total Assets
Based on the latest financial reports, Taiyen Biotech Co Ltd (1737) holds total assets worth NT$8.30 Billion TWD (≈ $261.41 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Taiyen Biotech Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Taiyen Biotech Co Ltd - Total Assets Trend (2003–2025)
This chart illustrates how Taiyen Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See Taiyen Biotech Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Taiyen Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Taiyen Biotech Co Ltd's total assets of NT$8.30 Billion consist of 33.4% current assets and 66.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.3% |
| Accounts Receivable | NT$533.71 Million | 6.5% |
| Inventory | NT$376.81 Million | 4.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$10.17 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Taiyen Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Taiyen Biotech Co Ltd (1737) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Taiyen Biotech Co Ltd's current assets represent 33.4% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2025, up from 1.7% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 6.5% of total assets.
Taiyen Biotech Co Ltd Competitors by Total Assets
Key competitors of Taiyen Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
Germany | €1.22 Trillion |
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
China | CN¥8.57 Billion |
|
Natura &Co Holding S.A.
SA:NTCO3
|
Brazil | R$34.86 Billion |
|
KP Tissue Inc
TO:KPT
|
Canada | CA$71.60 Million |
|
Suominen Oyj
HE:SUY1V
|
Finland | €278.77 Million |
|
Candles Scandinavia AB Series B
ST:CANDLE-B
|
Sweden | Skr347.00 Million |
|
Star Combo Pharma Ltd
AU:S66
|
Australia | AU$46.99 Million |
|
Mastrad
PA:ALMAS
|
France | €3.48 Million |
Taiyen Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.25 | 2.82 | 2.58 |
| Quick Ratio | 2.77 | 2.46 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.95 Billion | NT$1.86 Billion | NT$2.06 Billion |
Taiyen Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Taiyen Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | NT$8.26 Billion |
| Market Capitalization | $201.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Taiyen Biotech Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Taiyen Biotech Co Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Taiyen Biotech Co Ltd (2003–2025)
The table below shows the annual total assets of Taiyen Biotech Co Ltd from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$8.26 Billion ≈ $260.32 Million |
-1.42% |
| 2024-12-31 | NT$8.38 Billion ≈ $264.05 Million |
+0.74% |
| 2023-12-31 | NT$8.32 Billion ≈ $262.12 Million |
+1.32% |
| 2022-12-31 | NT$8.21 Billion ≈ $258.71 Million |
-3.02% |
| 2021-12-31 | NT$8.47 Billion ≈ $266.78 Million |
+8.59% |
| 2020-12-31 | NT$7.80 Billion ≈ $245.67 Million |
+2.58% |
| 2019-12-31 | NT$7.60 Billion ≈ $239.49 Million |
+3.76% |
| 2018-12-31 | NT$7.33 Billion ≈ $230.81 Million |
+1.09% |
| 2017-12-31 | NT$7.25 Billion ≈ $228.32 Million |
+2.75% |
| 2016-12-31 | NT$7.05 Billion ≈ $222.22 Million |
+2.95% |
| 2015-12-31 | NT$6.85 Billion ≈ $215.85 Million |
+1.68% |
| 2014-12-31 | NT$6.74 Billion ≈ $212.29 Million |
+9.18% |
| 2013-12-31 | NT$6.17 Billion ≈ $194.43 Million |
-10.15% |
| 2012-12-31 | NT$6.87 Billion ≈ $216.39 Million |
-1.40% |
| 2011-12-31 | NT$6.97 Billion ≈ $219.47 Million |
+0.22% |
| 2010-12-31 | NT$6.95 Billion ≈ $218.98 Million |
+0.78% |
| 2009-12-31 | NT$6.90 Billion ≈ $217.29 Million |
+3.49% |
| 2008-12-31 | NT$6.66 Billion ≈ $209.96 Million |
-4.79% |
| 2007-12-31 | NT$7.00 Billion ≈ $220.53 Million |
-6.16% |
| 2006-12-31 | NT$7.46 Billion ≈ $235.00 Million |
-4.69% |
| 2005-12-31 | NT$7.83 Billion ≈ $246.56 Million |
-20.45% |
| 2004-12-31 | NT$9.84 Billion ≈ $309.93 Million |
-14.39% |
| 2003-12-31 | NT$11.49 Billion ≈ $362.04 Million |
-- |
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.